Author information:
(1)Stem Cell Program, Division of Hematology/Oncology, Boston Children's 
Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and 
Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA.
(2)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK; Milner Therapeutics Institute, University of Cambridge, 
Puddicombe Way, Cambridge CB2 0AW, UK; Storm Therapeutics Ltd., Moneta Building 
(B280), Babraham Research Campus, Cambridge CB22 3AT, UK.
(3)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK.
(4)Department of Pathology, Cancer Center, Beth Israel Deaconess Medical Center, 
Boston, MA 02115, USA.
(5)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK; Karaiskakio Foundation, Nicandrou Papamina Avenue, 2032 
Nicosia, Cyprus.
(6)Division of Newborn Medicine and Epigenetics Program, Department of Medicine, 
Boston Children's Hospital, Boston, MA 02115, USA.
(7)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK; Cambridge Institute of Therapeutic Immunology & 
Infectious Disease (CITIID), University of Cambridge, Puddicombe Way, Cambridge 
CB2 0AW, UK.
(8)Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 
02115, USA.
(9)Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 
02115, USA; Department of Pediatrics, Harvard Medical School, Boston, MA 02115, 
USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
(10)Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge 
CB2 1EW, UK.
(11)Department of Biological Chemistry and Molecular Pharmacology, Harvard 
Medical School, Boston, MA 02115, USA; Department of Cancer Biology, Dana-Farber 
Cancer Institute, Boston, MA 02115, USA.
(12)Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), 
University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK.
(13)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK; Karaiskakio Foundation, Nicandrou Papamina Avenue, 2032 
Nicosia, Cyprus; Wellcome-MRC Cambridge Stem Cell Institute, University of 
Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK.
(14)Department of Pathology, Cancer Center, Beth Israel Deaconess Medical 
Center, Boston, MA 02115, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, 
USA; Harvard Initiative for RNA Medicine, Boston, MA 02115, USA.
(15)Haematological Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, 
Cambridge CB10 1SA, UK; Milner Therapeutics Institute, University of Cambridge, 
Puddicombe Way, Cambridge CB2 0AW, UK; Wellcome-MRC Cambridge Stem Cell 
Institute, University of Cambridge, Puddicombe Way, Cambridge CB2 0AW, UK. 
Electronic address: kt404@cam.ac.uk.
(16)Stem Cell Program, Division of Hematology/Oncology, Boston Children's 
Hospital, Boston, MA 02115, USA; Department of Biological Chemistry and 
Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA; Division 
of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA; 
Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA; Harvard 
Stem Cell Institute, Cambridge, MA 02138, USA; Harvard Initiative for RNA 
Medicine, Boston, MA 02115, USA. Electronic address: 
rgregory@enders.tch.harvard.edu.